GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » Selling and Marketing Expense

Defence Therapeutics (XCNQ:DTC) Selling and Marketing Expense : C$2.14 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Defence Therapeutics's Selling and Marketing Expense for the three months ended in Dec. 2023 was C$0.51 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Dec. 2023 was C$2.14 Mil.

Defence Therapeutics Selling and Marketing Expense Historical Data

The historical data trend for Defence Therapeutics's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics Selling and Marketing Expense Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22
Selling and Marketing Expense
- 0.34 2.52

Defence Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.26 0.77 0.85 0.51

Defence Therapeutics Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$2.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Defence Therapeutics Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Defence Therapeutics (XCNQ:DTC) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » Selling and Marketing Expense
Comparable Companies
TSX:EPRX NEOE:MMED TSXV:NGEN TSX:BCT TSX:ONC XCNQ:MSET TSXV:ARCH TSXV:MIR TSXV:DMT TSX:HBP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
DTCFF:USA DTC:Germany
Address
200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6
Website
https://www.defencetherapeutics.com
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.
Executives
Sarkis Meterissian Director